Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-146567 · Präparat HOS-099534
Non nucleoside reverse transcriptase inhibitors efavirenz. Combination with other medicines for advanced hormone-sensitive prostate cancer Abiraterone Therapeutic Expected: ↔ Expected: ↔ Abiraterone and dose for docetaxel are not Orgovyx known 8 (not an inhibitors/inducers of inhibitor/inducer of enzymes and CYP3A4 and/or P-gp) transporters contributing to the Docetaxel Therapeutic Expected: ↔ Expected: ↔ metabolism and dose for Orgovyx transport of relugolix. (not an inhibitor/inducer of CYP3A4 and/or P-gp) No clinically meaningful interaction is expected and no dose adjustment of Orgovyx is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) efavirenz (HOS-087947) abiraterone (HOS-125270)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage 066f63f631e70ae149b7529b100c7bf74fe9bcc9c665bd5dcfd694de48d09ee4 · Zeichen 9163–10761 im Abschnitt